Longevity Startups Have a Conundrum: Can They Sell Longevity Drugs? (The Information) (opens in new tab)

In many ways, these are the best of times for Silicon Valley’s buzziest crop of longevity startups and their pursuit of drugs that can reverse aging. NewLimit, a cell reprogramming company co-founded in 2022 by Coinbase CEO Brian Armstrong, announced earlier this month that it had raised another $435 million and plans to start testing a drug in humans next year. In all, it has collected over $630 million in funding. Retro Biosciences, a startup launched in 2022 with $180 million from OpenAI’s...